September 19th, 2025
Description
Sarcoma is a rare cancer, comprising only 1% of adult malignancies, with over 100 distinct subtypes. Effective treatment requires a multidisciplinary approach, tailored to the specific subtype, with precise timing and modalities. While progress in research has been slow, leading to limited new treatments, recent advancements offer new hope. These include next-generation sequencing, biomarkers, proton therapy, and immunotherapy. However, physicians outside of large referral centers often face a gap in understanding and applying these cutting-edge treatments. We are privileged to welcome Dr. Silvia Stacchiotti, MD, a world-renowned expert in sarcoma, who will be joined by other leading specialists from the James Cancer Center to share their expertise on these emerging therapies and advancements.
For pricing information, see pricing tab below.
Dates and Times
Start: 9/19/2025 12:00 AM
End: 9/19/2025 12:00 AM
Objectives
1. Describe the latest and best practices for multidisciplinary sarcoma management
2. Explain the use of genomics and circulating biomarkers in sarcoma treatment
3. Identify patients for whom proton radiation therapy would provide benefit over photon radiation
4. Define the different types of sarcoma and approaches to treatment and expected outcomes
5. Articulate patients for whom immunotherapy is indicated
6. Explain the different options for reconstruction and the impact of surgical resection, radiation and chemotherapy on reconstruction
Pricing
| Tier | Price |
|---|---|
| Physician | $60.00 |
| Fellow/Trainee | $0.00 |
| Nurse/APP | $40.00 |
Location
The Event Center at MItchell Hall
250 Cleveland Ave.
Columbus, OH 43215
Accreditation Statement
The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The Ohio State University designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.